Ralph J A Maas (Ralph Ja Maas, R J A Maas)

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 3

Top Topics

Signaling Pathway

Virtual Reality

Top Venues

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Jolien M R Van der Meer, Paul K J D de Jonge, Anniek B van der Waart, Alexander C Geerlings, Jurgen P Moonen, Jolanda Brummelman, Janne de Klein, Malou C Vermeulen, Ralph J A Maas, Nicolaas P M Schaap, J S Hoogstad-van Evert, Petronella B Ottevanger, Joop H Jansen, Willemijn Hobo, Harry Dolstra
CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice. Oncoimmunology 10 (1) (2021)
Jolien M R Van der Meer, Ralph J A Maas, Karolin Guldevall, K Klarenaar, P K J D de Jonge, J S Hoogstad-van Evert, Anniek B van der Waart, J Cany, J T Safrit, J H Lee, E Wagena, Peter Friedl, Björn Önfelt, Leon F A G Massuger, Nicolaas P M Schaap, Joop H Jansen, Willemijn Hobo, Harry Dolstra
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer immunology, immunotherapy : CII 70 (5) (2020)
Ralph J A Maas, J S Hoogstad-van Evert, Jolien M R Van der Meer, Vera Mekers, Somayeh Rezaeifard, Alan J Korman, Paul K J D de Jonge, Jeannette Cany, Rob Woestenenk, Nicolaas P M Schaap, Leon F Massuger, Joop H Jansen, Willemijn Hobo, Harry Dolstra
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology 9 (1) (2020)